---
$id: https://graph.org.ai/products/commodity/51111633
$type: Product
source: UNSPSC
code: "51111633"
title: "Edatrexate"
class: "51111600"
classTitle: "Antimetabolites"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Edatrexate

**UNSPSC Code**: 51111633
**Class**: [Antimetabolites](Antimetabolites.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a folate antagonist and dihydrofolate reductase inhibitor with the molecular formula C22H25N7O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JT4X6Z1HRR, chemically known as n-(p-(1-((2,4-diamino-6-pteridinyl)methyl)propyl)benzoyl)-l-glutamic acid but generally known as edatrexate, which bears US NIH Compound Identifier 54586. European Medicines Agency schedules Edatrexate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06454MIG. The term EDATREXATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). EDATREXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule edatrexate under HS 29335995 and SITC 51576. As of Q4 2014, EDATREXATE remains the US FDA Preferred Term for this commodity. Edatrexate bears US NLM identifiers UMLS ID C0044667 and NCI Concept Code C958. SMILES: O=C(NC(CCC(=O)O)C(=O)O)C1CCC(C(CC2NC3C(NC2)NC(NC3N)N)CC)CC1.

